3,6-di-n-butyl-hexahydro-s-tetrazine | 94981-05-2

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 3,6-di-n-butyl-hexahydro-s-tetrazine
• 英文别名: 3,6-Dibutyl-hexahydro-1,2,4,5-tetrazin；3,6-dibutyl-[1,2,4,5]tetrazinane；3,6-Dibutyl-1,2,4,5-tetrazinane
• CAS: 94981-05-2
• 化学式: C₁₀H₂₄N₄
• 分子量: 200.327
• InChiKey: TVUMUPKGSJVRAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  48.1
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 3,6-di-n-butyl-hexahydro-s-tetrazine 以63.4%的产率得到1-(4-Acetyl-3,6-dibutyl-[1,2,4,5]tetrazinan-1-yl)-ethanone
  参考文献：
  名称：

  Synthesis and antitumor activity of s -tetrazine derivatives

  摘要：

  Fifty-five compounds of s-tetrazine derivative including hexahydro-, 1,6-dihydro, 1,4-dihydro-, 1,2-dihydro- and aromatic s-tetrazine were prepared. Their antitumor activities were evaluated in vitro by MTT method for P-388 cell and SRB method for A-549 cell. The results show that there are 9 compounds which in 10(-6) muM have more than 50% inhibition rate to A-549 cancer cell growth, and 7 compounds in 10(-6) muM have more than 50% inhibition rate to P-388 cancer cell growth. The IC50 of compound 3q for P-388, Bel-7402, MCF-7 and A-549 are 0.6 muM, 0.6 muM, 0.5 muM and 0.7 muM, respectively. So s-tetrazine derivative is a kind of compound which possesses potential antitumor activities and is worth to research further. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.056
• 作为产物：
  描述：

  正戊醛 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 3,6-di-n-butyl-hexahydro-s-tetrazine
  参考文献：
  名称：

  3,6-二烷基-1,6-二氢-s-四嗪的简便制备

  摘要：

  摘要 1,6-二氢-s-四嗪类化合物 1，在杂环的 3-位和 6-位具有多种取代基，已被合成，由于它们的同芳香性和潜在的反应性，已经引起了越来越多的关注。更多的兴趣 (Sauer, J. 1,2,4,5-Tetraazines. In Comprehensive Heterocyclic Chemistry II; Boultou, AJ, Ed.; Elsevier: Oxford, UK, 1996; Vol. 6, 901; Neunhoeffer, H In Comprehensive Heterocyclic化学 I；Katritzky, A., Ed.；Pergamon Press Ltd.：德意志联邦共和国，1984；第 3 卷，545）。

  DOI：

  10.1081/scc-120022164

文献信息

• NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA
  申请人：University of Florida Research Foundation, Inc.

  公开号：US20130281389A1

  公开（公告）日：2013-10-24

  Topoisomerase II alpha (topo IIα) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo IIα is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo IIα to the export receptor CRM1. Inhibition was specific to topo IIα as p53 trafficking was unaffected along with topo IIα protein expression and function (decatenation). These topo IIα-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor.
• US9616051B2
  申请人：——

  公开号：US9616051B2

  公开（公告）日：2017-04-11